GLAXOSMITHKLINE PLC Form 6-K September 17, 2012

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending September 2012

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

_

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

			_					~ .	_
Notification of	f Transactions	of Directors	Persons	Dischargin	ισ Mana	gerial Rec	noncihility	or Connected	Persons
1 totti Cation of	i i i ansacuons	or Directors,	1 CISOIIS	Dischargh	ig iviana	gerrar rees	ponsionity	or Connected	I CISOIIS

Following a revaluation of the cash element of the notional investment held within the US Retirement Savings Plan (The Plan), which is notionally held in GSK American Depositary Shares (ADSs), the Administrators of the Plan notified GlaxoSmithKline plc and the under-mentioned Persons on 17 September 2012 of an increase in the notional allocation of ADSs on 14 September 2012 at a price of \$45.90 per ADS:-

Director/PDMR Number of ADSs

Connected Person Number of ADSs

Dr M M Slaoui - Dr K Slaoui 3

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).

V A Whyte Company Secretary

17 September 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Date: September 17, 2012

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc